市場調查報告書
商品編碼
1355829
藥物發現市場中的人工智慧(AI)-按組件(軟體、服務)、技術(機器學習{深度學習})、應用類型(目標識別)、治療領域(腫瘤學)、最終用途(CRO)、全球預測, 2023-2032Artificial Intelligence (AI) in Drug Discovery Market-By Component (Software, Service), Technology (Machine learning {Deep Learning}), Application Type (Target Identification), Therapeutic Area (Oncology), End-use (CRO), Global Forecast, 2023-2032 |
在越來越多的跨產業合作和夥伴關係的推動下,藥物發現市場中的全球人工智慧 (AI) 將從 2023 年到 2032 年以 30.1% 的複合年成長率成長。製藥專業知識與人工智慧驅動技術的融合可實現更快、更有效率的藥物發現過程。合作促進了人工智慧演算法與藥物研究的整合,加速了潛在化合物的識別並縮短了開發時間。不同部門之間的協同作用促進了創新,推動了人工智慧在藥物發現產業的發展。
舉個例子,2023 年 10 月,Evozyn 透露完成了 8,100 萬美元的 B 輪融資,致力於支持其人工智慧驅動的生成藥物發現平台和產品開發工作的進展。這項進展是在 2023 年初與 NVIDIA 建立富有成效的合作關係之後推出的,在此期間,兩家公司共同創建了一個能夠設計治療性蛋白質的創新人工智慧模型。
藥物發現市場中的整體人工智慧根據組件、技術、應用、治療領域、最終用途和地區進行分類。
服務部門可能在 2023 年至 2032 年期間獲得可觀的利益。藥物發現服務中的人工智慧需求量很大,因為它們能夠顯著加快藥物開發過程。人工智慧演算法可以分析大量資料集,預測潛在的候選藥物,並以驚人的速度和精確度最佳化分子結構。這不僅縮短了研發時間,也降低了成本。隨著對更快、更有效率的藥物發現解決方案的需求,該領域對人工智慧服務的需求持續成長。
到 2032 年,藥物發現解決方案和服務中的人工智慧可能會在臨床前測試應用中遇到激增的需求,因為它們提高了準確性和效率。人工智慧驅動的演算法可以快速分析複雜的生物和化學資料,幫助識別有前途的候選藥物並預測它們在臨床前測試中的行為。這減少了對大量實驗室實驗的需求,加快了藥物開發時間,並最終降低了成本,使得人工智慧在藥物發現的臨床前測試階段不可或缺。
2023 年至 2032 年間,歐洲藥物發現產業的人工智慧可能呈現顯著的複合年成長率。歐洲擁有強大的製藥業,並且正在大力投資人工智慧研究。根據 EFPIA 2022 年年度報告,歐洲研究型製藥產業產值大幅成長,從 2000 年的 1,275 億歐元成長到 2021 年的 3,000 億歐元。同期為 909 億歐元至 5,650 億歐元。 2021年進口額達3,900億歐元,貿易順差達1,750億歐元。
對創新的監管支援以及學術界、新創公司和老牌製藥公司之間的合作夥伴關係促進了人工智慧的採用。此外,需要更有效率的藥物開發流程來對抗 COVID-19 等疾病,這加速了整個歐洲地區對藥物發現中人工智慧解決方案的需求。
Global Artificial Intelligence (AI) in Drug Discovery Market will expand at 30.1% CAGR from 2023 to 2032, driven by the growing number of cross-industry collaborations and partnerships. The convergence of pharmaceutical expertise with AI-driven technologies enables faster and more efficient drug discovery processes. Collaborations facilitate the integration of AI algorithms into drug research, accelerating the identification of potential compounds and reducing development timelines. This synergy between different sectors fuels innovation, driving the growth of the AI in drug discovery industry.
Quoting an instance, in October 2023, Evozyn revealed the completion of an $81 million Series B funding round dedicated to supporting the advancement of its generative AI-powered drug discovery platform and product development efforts. This development comes on the heels of a productive partnership with NVIDIA earlier in 2023, during which the two companies jointly created an innovative AI model capable of designing therapeutic proteins.
The overall AI in drug discovery market is categorized based on component, technology, application, therapeutic area, end-use, and region.
The services segment could garner commendable gains throughout 2023-2032. AI in drug discovery services is in high demand due to their ability to significantly expedite the drug development process. AI algorithms can analyze vast datasets, predict potential drug candidates, and optimize molecular structures with remarkable speed and precision. This not only reduces research and development timelines but also lowers costs. With the need for faster and more efficient drug discovery solutions, the demand for AI services in this sector continues to grow.
AI in drug discovery solutions and services could experience surging demand in preclinical testing applications by 2032 because they enhance accuracy and efficiency. AI-powered algorithms can swiftly analyze complex biological and chemical data, aiding in the identification of promising drug candidates and predicting their behavior in preclinical testing. This reduces the need for extensive laboratory experiments, accelerates the drug development timeline, and ultimately lowers costs, making AI indispensable in the preclinical testing phase of drug discovery.
Europe AI in drug discovery industry could exhibit noteworthy CAGR between 2023-2032. Europe boasts a strong pharmaceutical sector and is investing significantly in AI research. According to EFPIA's Annual Report for 2022, the research-based pharmaceutical industry in Europe has seen substantial growth in production value, rising from 127.5 billion euros in 2000 to 300 billion euros in 2021. Equally noteworthy is the remarkable increase in exports, which surged from 90.9 billion euros to 565 billion euros during the same timeframe. In 2021, imports accounted for 390 billion euros, resulting in a positive trade balance of 175 billion euros.
Regulatory support for innovation and partnerships between academia, startups, and established pharmaceutical companies fosters AI adoption. Additionally, the need for more efficient drug development processes to combat diseases like COVID-19 accelerates the demand for AI solutions in drug discovery across the European region.